Jan 05, 2026
Amazon Launches Alexa+ Website To Rival ChatGPT

Amazon.com Inc (NASDAQ:AMZN) is expanding Alexa+ to the web as it ramps up competition with leading artificial intelligence chatbots. On Monday, Amazon launched Alexa.com, a browser-based experience that allows users to interact with Alexa+ directly from a desktop or laptop.…

Jan 05, 2026
Why Are Defense Stocks Rising Today?

Shares of defense stocks are rising Monday after the United States seized former Venezuelan president Nicolás Maduro and his wife in a weekend operation. Which Defense Stocks Are Moving? Lockheed Martin Corporation (NASDAQ:LMT), Northrop Grumman Corporation (NASDAQ:NOC), Palantir Technologies Inc.…

Jan 05, 2026
Qualcomm Turns ‘Physical AI’ From Buzzword Into Reality

At CES 2026, Qualcomm Inc. (NASDAQ:QCOM) aggressively positioned itself as the central architect of the “connected edge,” providing full-stack ecosystems for IoT, robotics, and automotive sectors. Unifying IoT and Next-Gen Robotics Qualcomm is consolidating the fragmented Internet of Things market…

Jan 05, 2026
Maduro Down, Drone Stocks Up After Venezuela Mission

The U.S.’s capture of Venezuela President Nicolás Maduro on Saturday, Jan. 3, triggered a massive rally in drone stocks as markets opened on Monday.  AVAV stock is climbing. See the chart and price action here.  Investors are aggressively pivoting toward…

Jan 05, 2026
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer

Incyte Corporation (NASDAQ:INCY) on Monday shared topline results from the pivotal Phase 3 frontMIND trial of tafasitamab (Monjuvi/Minjuvi) combo as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The trial evaluated tafasitamab and lenalidomide in…

Jan 05, 2026
L3Harris Sells Majority Stake In Space Propulsion Unit

L3Harris Technologies, Inc. (NYSE:LHX) announced on Monday that it has agreed to sell a controlling interest in its Space Propulsion and Power Systems business to AE Industrial Partners, a private investment firm focused on aerospace and national security technologies. The…

Jan 05, 2026
Neumora’s Alzheimer’s Agitation Drug Shows Early Promise

Neumora Therapeutics, Inc. (NASDAQ:NMRA) on Monday shared results from its Phase 1b signal-seeking study of NMRA-511 for Alzheimer’s disease (AD) agitation. NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation. In the study, NMRA-511 demonstrated a favorable…